Val-boroPro can increase the prevalence of cytotoxic T cells and natural killer cells when used in conjunction with an antibody to programmed cell death protein 1 (PD1), develop anti-tumour T-cell memory, and reduce pancreatic ductal adenocarcinoma tumour burden in mice [112]. This evidence concerns the gene PDCD1 and pancreatic ductal adenocarcinoma.